Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Naproxen in Lynch Syndrome
NCT02052908Phase 1Completed
- Sponsor
- National Cancer Institute
- Start
- Jan 2014
- Primary completion
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of naproxen in colorectal cancer (CRC) (3 arms), sponsored by National Cancer Institute. Primary endpoints: Change in Prostaglandin E2 concentration levels in normal colorectal mucosa at 6 months and Incidence of toxicity at 6 months. Started Jan 2014; status: completed.
02
Drugs
naproxen
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT02052908.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02052908.